• Explore /
  • Poster
  • / Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.

Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.

Abstract Poster

Authors

null

David Shao Peng Tan

National University Cancer Institute, Singapore (NCIS), Singapore, Singapore

David Shao Peng Tan , Mei-Yan Pang , Wei Peng Yong , Ross A. Soo , Cheng Ean Chee , Yee Liang Thian , Anil Gopinathan , Andrea Li Ann Wong , Priscillia Koe , Raghav Sundar , Jingshan Ho , Sharon Friedlander , Yosef Landesman , Tami Rashal , Dilara McCauley , Sharon Shacham , Soo Chin Lee , Boon C. Goh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT02078349

Citation

J Clin Oncol 33, 2015 (suppl; abstr 2542)

DOI

10.1200/jco.2015.33.15_suppl.2542

Abstract #

2542

Poster Bd #

258

Abstract Disclosures

Similar Posters

First Author: Morten Mau-Soerensen

First Author: Funda Meric-Bernstam

First Author: Soohyeon Lee

First Author: Jessica Dreger McDermott